Novartis AG (NOVN)

87.82
+0.14(+0.16%)
  • Volume:
    3,698,480
  • Bid/Ask:
    87.81/87.83
  • Day's Range:
    87.75 - 88.42
  • Type:Equity
  • Market:Switzerland
  • ISIN:CH0012005267
  • S/N:1200526

NOVN Overview

Prev. Close
87.68
Day's Range
87.75-88.42
Revenue
48.34B
Open
88
52 wk Range
72.85-88.41
EPS
10.31
Volume
3,698,480
Market Cap
190.18B
Dividend (Yield)
3.10
(3.53%)
Average Volume (3m)
5,500,549
P/E Ratio
8.46
Beta
1.02
1-Year Change
10.53%
Shares Outstanding
2,171,940,280
Next Earnings Date
18 Jul 2022
What is your sentiment on Novartis?
or
Market is currently closed. Voting is open during market hours.

Novartis AG News

Novartis AG Analysis

Novartis AG Company Profile

Novartis AG Company Profile

Employees
108000

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellSellStrong BuyStrong Buy
SummaryStrong SellStrong SellNeutralStrong BuyStrong Buy
  • Novartis is trading at a value last seen in 2018; the funds released from a Sandoz divestment need to be directed towards further patient innovation from this Swiss Pharma major …
    0
    • Hi Guys, I have been invested in Novartis for 5 years and have closely followed the pharmaceutical industry for years. I have been very disappointed with the returns and am looking to transfer my portfolio into riskier assets. Upon research, I think I may have found an even better pharmaceutical company going by the name of SpectrumX. SpectrumX are leaders in patented shielded HOCL formulations that have numerous applications in medical/pharma fields. They have also undergone 2 clinical trials for Covid-19 treatment (apparently not factored into the company valuation.) To me this company seems to be on track for high growth after the IPO, however I may be getting lost in the hype. Would love to hear people's thoughts on the stock as I am keen to invest early.
      1